
In first open-label phase 3 data from the ADEPT program, KarXT cut hallucination and delusion scores in Alzheimer disease psychosis, with no new safety signals.
Stimulant use can worsen psychotic symptoms in persons with schizophrenia and schizoaffective disorder.




